News

Fierce Pharma18h
Gilead's Trodelvy-Keytruda proposal hits goal in first-line triple-negative breast cancer
In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...
Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts
Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...